Autobio Diagnostics Co Ltd
SSE:603658
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
38.18
66.36
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Autobio Diagnostics Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | CN |
Market Cap | 25.7B CNY |
Net Margin |
28%
|
Country | JP |
Market Cap | 6.8T JPY |
Net Margin |
24%
|
Country | CH |
Market Cap | 37.9B CHF |
Net Margin |
12%
|
Country | DK |
Market Cap | 200.9B DKK |
Net Margin |
19%
|
Country | US |
Market Cap | 16.9B USD |
Net Margin |
11%
|
Country | KR |
Market Cap | 9.9T KRW |
Net Margin |
-358%
|
Country | CA |
Market Cap | 6.9B USD |
Net Margin |
-8%
|
Country | CN |
Market Cap | 48.6B CNY |
Net Margin |
42%
|
Country | US |
Market Cap | 6.3B USD |
Net Margin |
29%
|
Country | US |
Market Cap | 6.1B USD |
Net Margin |
9%
|
Country | UK |
Market Cap | 4.8B GBP |
Net Margin |
7%
|
Autobio Diagnostics Co Ltd
Glance View
Autobio Diagnostics Co., Ltd. engages in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. The company is headquartered in Zhengzhou, Henan and currently employs 5,031 full-time employees. The company went IPO on 2016-09-01. The firm's main products include gnostic products, microbiology detection products, and related devices. The immunodiagnostic products include microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The microbiology detection products include training detection reagents, susceptibility detection reagents and rapid detection reagents. The device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. The firm distributes its products in domestic markets.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Autobio Diagnostics Co Ltd's most recent financial statements, the company has Net Margin of 28.4%.